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INTRODUCTION 
 
G-protein-coupled receptors (GPCRs), the largest class of 
cell-surface receptors, are one of the major targets for many current 
and emerging drugs. Recent developments indicate novel levels of 
regulations of GPCRs functioning, such as cross-talk at the level of 
signaling, constitutive activity and oligomerization of GPCRs. The 
regulations of GPCRs at multiple levels cause emergence of 
complexity and specificity of GPCRs targeting.  
Cannabinoid CB1 (CB1) receptors are the most abundant 
GPCRs in the brain, with levels ten-fold higher than those of other 
GPCRs. The CB1 receptor displays a significant level of constitutive 
activity, either in non-neuronal cells or in neurons. Increasing 
number of evidences indicate that the CB1 receptors show different 
levels of interaction with other receptor types. Particularly, the CB1 
receptor system shares several features with both the µ-opioid 
(MOR) and the GABAB receptor systems. The pattern of expression 
of the CB1 receptors strongly overlaps with that of the GABAB and 
the µ-opioid receptors in certain central nervous sytems (CNS) 
regions. All three receptor systems are predominantly coupled to 
heteorotrimeric Gi/o-proteins. Several studies have revealed a 
functional interaction of the CB1 receptors with the GABAB and the 
MORs at the level of G-proteins in certain regions of the CNS. 
Importantly, CB1, GABAB and MORs have been shown to display 
similar pharmacological effects, particularly on pain. 
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The first highly selective CB1 receptor antagonist, 
SR141716 that was used in the clinics under the name Rimonabant to 
reduce obesity has been shown to exert a plethora of 
pharmacological effects in a number of pathological conditions. 
These effects are mainly attributed to its antagonistic properties at 
the CB1 receptors, although there is increasing evidence that it may 
also behave as an inverse agonist. However, recent studies have 
revealed the existence of CB1 receptor-independent actions of CB1 
inverse agonists. It has been proposed that the inhibitory effect of 
SR141716 on the basal receptor activity might occur either via a 
non-receptor-mediated effect or by binding to a site other than the 
agonist binding site on the CB1 receptors, or by binding to GPCRs 
other than the CB1 receptors, to which it binds with much lower 
affinity. Although there are data supporting these notions, the exact 
mechanism of inverse agonism by SR141716 has not been clarified 
yet. 
The GABAB receptors are highly unusual among GPCRs in 
their requirement for heterodimerization between two subunits, the 
GABAB1 and the GABAB2 for functional expression. Immuno-
electron microscopic studies have suggested that the GABAB2 
subunit may be absent, but electrophysiological data have shown the 
presence of functional GABAB autoreceptors in CCK-containing 
interneurons in rat hippocampus (T. Freund, personal 
communication). This observation raises the possibility that the 
GABAB1 may function in association with additional interacting 
 3 
partners, for example a yet unidentified GABAB receptor subunit, a 
distinct GPCR, or a chaperoning protein. 
 
 
 
 4 
AIM OF THE STUDIES 
 
The present work consists of two distinct, but related studies 
about the promiscuity of the CB1 receptor system. In the first part, 
our goal was to reveal possible interaction between the CB1 and 
GABAB receptors.  Previous literature data have raised the 
possibility that the well-known CB1 receptor antagonist, SR141716 
may have some non-CB1 receptor mediated inverse agonist effects. 
Thereby, in the second part of our work, we have performed a 
detailed study on the promiscuous action of SR141716. 
 
The current work focused on  
 
1. Investigating if there is functional interaction of the CB1 
and GABAB receptors at the G-protein level in rat hippocampus.  
Thereby, we have studied: 
 
 if there are functional GABAB and cannabinoid CB1 
receptors in rat hippocampal membranes; 
 
 whether CB1 and GABAB receptors interact on G-protein 
signaling and if so what are the pharmacological 
consequences; 
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  what may be the mechanism? Cross-talk, hetero-
oligomerization, or? 
 
2. Assessing the inverse agonist effect of SR141716. The 
following questions have been investigated:  
 
 is the inverse agonist effect mediated via the CB1 receptors? 
Under what conditions? 
 
  or does it occur via binding to GPCRs other than the CB1 
receptors, e.g. MOR?  
 
  or is it a  non-receptor-mediated effect? 
 
Hence, we have used tissues containing distinct populations 
of receptors that a)  contain both the CB1 receptors and the MORs 
(wild-type, wt mouse cerebral cortex); b)  lack the CB1 receptors 
(CB1 receptor knock-out,  CB1-KO mouse cerebral cortex); c)  lack 
both the CB1 receptors and the MORs (parental Chinese hamster 
ovary, CHO cells); or  d) contain a homogeneous population of over-
expressed recombinant MORs (MOR-CHO cells), which were either 
untreated or made morphine-tolerant. 
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METHODS 
Animals 
Rats (Wistar male, 200-250 g, inbred in the BRC, Szeged, 
Hungary) and mice (CD1 male, 20-25 g) were handled in accordance 
with the European Communities Council Directives (86/609/EEC), 
and the Hungarian Act for the Protection of Animals in Research 
(XXVIII.tv. Section 32). CB1-KO mutant mice generated as 
described (Ledent et al., 1999, Science 283, 401-404) were provided 
by Dr. Freund, Institute of Experimental Medicine, Budapest, 
Hungary).  
 
Brain membrane preparation 
Animals were decapitated, their brains removed, followed 
by dissection of hippocampus or cortex on ice. The tissues were 
washed with ice-cold buffer and their weight measured. They were 
homogenized in 30 volume (v/w) of ice-cold 50 mM Tris-HCl buffer 
(pH 7.4) with 5 strokes in a teflon-pestle Braun homogenizer at 1500 
U/min. Homogenates were centrifuged at 20,000 x g for 25 min, the 
resulting pellets suspended in buffer and spun again. Pellets were 
taken up in the original volume of buffer and incubated for 30 min at 
37 0C, followed by centrifugation at 20,000 x g for 25 min. The 
supernatants were carefully discarded, and the final pellets taken up 
in 5 volumes (v/w) of 50 mM Tris-HCl buffer (pH 7.4) containing 
0.32 M sucrose. Appropriate membrane aliquots were stored at –80 
0C for several weeks.  
 
Rat spinal cord membrane preparation 
Rat spinal cords were dissected and stored at –80 0C for 
several weeks. They were thawed before use and homogenized in 10 
volume (v/w) of ice-cold 50 mM Tris-HCl buffer (pH 7.4) with 5 
strokes in a teflon-pestle Braun homogenizer at 700 U/min. 
Homogenates were centrifuged at 5,000 x g for 10 min. The 
supernatant was carefully decanted and stored on ice. The pellet was 
suspended in the original volume of buffer and spun as above. The 
combined supernatants of the two centrifugation steps were spun at 
20,000 x g for 25 min. The resulting pellet was taken up in the original 
volume of buffer and incubated for 30 min at 37 0C, followed by 
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centrifugation at 20,000 x g for 25 min. The supernatant was 
carefully discarded. The final pellets were taken up in 20 volumes 
(v/w) of 50 mM Tris-HCl buffer (pH 7.4) and freshly used in the 
functional assay.  
 
Cell culture and treatment 
CHO cells stably transfected with the MORs (MOR-CHO) 
were cultured as previously described (Szücs et al., 2004, J 
Pharmacol Exp Ther 310, 256-262). Briefly, the cells were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM) high 
glucose with L-glutamine supplemented with 10% fetal calf serum. 
1% penicillin/streptomycin and 3.6% geneticin.. Cells were grown at 
370C in a humidified atmosphere of 10% CO2, 90% air. One set of 
cells were treated with 100 ng/ml pertussis toxin (PTX) for the last 
24 h in culture. At the end of PTX exposure, the cells were washed 
twice with ice-cold phosphate-buffered saline (PBS). The cells were 
harvested with PBS containing 1 mM EDTA. Cell suspension was 
spun at 2,500 rpm for 5 min, after which preparation of the cell 
membranes commenced. 
 
Cell membrane preparation 
Freshly collected cell pellets were homogenized with a 
Wheaton teflon-glass homogenizer in 10 vols (v/w) of ice-cold 
homogenization buffer, pH 7.4, composed of 25 mM HEPES, 1 mM 
EDTA, 0.5 mg/l aprotinin, 1 mM benzamidine, 100 mg/l bacitracin, 
3.2 mg/l leupeptin, 3.2 mg/l soybean trypsin inhibitor and 10% 
sucrose as reported earlier (Szücs et al., 2004, J Pharmacol Exp Ther 
310, 256-262).  Homogenates were spun at 1,000 x g for 10 min at 4 
oC, and the supernatant was collected. Pellets were suspended in half 
of the original volumes of the homogenization buffer and centrifuged 
as above. Combined supernatants from the two low-speed 
centrifugations were spun at 20,000 x g for 30 min. The cell pellets 
were taken up in appropriate volumes of homogenization buffer. 
Aliquots were stored at -80 oC until use.  
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Protein determination 
The protein content of the membrane preparations was 
determined by the method of Bradford, BSA being used as a standard 
(Bradford, 1976, Anal Biochem 36, 708-719).  
 
Ligand-stimulated [35S]GTPγS binding assay 
The assay was performed as described (Fabian et al., 2002) 
except that the concentration of GDP (3 µM) and NaCl (100 mM) 
was optimized for both CB1 and GABAB agonists in rat 
hippocampus, cortex and spinal cord in preliminary experiments. The 
concentration of GDP was optimized at 3 and 30 µM for MOR-CHO 
cells and mouse cortex membranes, respectively. The highest 
concentrations of the solvents (0.1% ethanol or DMSO) tested in 
preliminary experiments had no effect on the basal activity in the assay.  
Briefly, crude membrane fractions (10 µg of protein) were incubated 
with 0.05 nM [35S]GTPγS and appropriate concentrations of  ligands 
in TEM buffer (50 mM Tris-HCl, 1 mM EGTA and 3 mM MgCl2, 
pH 7.4) containing appropriate concentrations of GDP, 100 mM 
NaCl and 0.1% (w/v) BSA in a total volume of 1 ml for 60 min at 30 
°C. Nonspecific binding was determined with 10 µM GTPγS and 
subtracted to yield specific binding values. Bound and free 
[35S]GTPγS were separated by vacuum-filtration through Whatman 
GF/F filters with a Brandel Cell Harvester . Filters were washed with 
3 × 5 ml of ice-cold buffer, and radioactivity of the dried filters was 
detected in a toluene-based scintillation cocktail in a Wallac 1409 
scintillation counter. . 
 
Radioligand binding assay 
Heterologous displacement assays were performed with a 
constant concentration (1 nM) of [3H]DAMGO (spec. activity 36 
Ci/mmol), 11 concentrations (10-10-10-5 M) of unlabeled Win55,212-
2 or SR141716 and MOR-CHO membrane suspension (10 µg 
protein) in 50 mM Tris-HCl pH 7.4 buffer containing 0.1% (w/v) 
BSA in a final volume of 1 ml.  Nonspecific binding was defined as 
the radioactivity bound in the presence of 10 µM unlabeled naloxone, 
and was subtracted from the total binding to obtain the specific 
binding.  The tubes were incubated at 25 °C for 1 h.  The reaction 
was stopped by vacuum filtration through Whatman GF/C glass fiber 
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filters using a Brandel M24-R Cell Harvester   Filters were rapidly 
washed with 3 x 5 ml of ice-cold 50 mM Tris-HCl pH 7.4 buffer, air-
dried and counted in a toluene-based scintillation cocktail in a 
Wallac 1409 scintillation counter. All assays were performed in 
duplicate and repeated at least three times.   
 
Data analysis 
The dose-response curves in the ligand-stimulated 
[35S]GTPγS binding assay were drawn and analyzed with the 
GraphPad Prism 4.0 software using nonlinear regression and 
sigmoidal curve fitting to obtain potency (EC50: the ligand 
concentration that elicits half-maximal effect) and efficacy (Emax: 
maximal effect) values. Basal activities were measured in the 
absence of receptor ligands and defined as 0% in each experiment 
unless otherwise indicated. All data are expressed as percentages of 
the basal [35S]GTPγS binding and are the means ± S.E.M. of the 
result of at least three independent experiments performed in 
triplicate. IC50 (the concentration of ligand required to achieve 50% 
inhibition) values were obtained from the radioligand displacement 
curves using  GraphPad Prism Software. All receptor binding data 
are expressed as percentage inhibition of specific binding and are the 
means ± S.E.M. of the result of at least three independent 
experiments performed in duplicate. Statistical analysis was 
performed with GraphPad Prism, using ANOVA or Student`s t-test 
analysis. Significance was defined at p < 0.05 level. 
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SUMMARY OF THE RESULTS 
The main results are the following: 
 
1) The GABAB receptor antagonist, phaclofen at low doses (1 and 
10 nM) significantly attenuated G-protein signaling of the CB1 
agonist Win55,212-2 in rat hippocampal membranes. High 
concentrations of phaclofen had no effect, ruling out the 
possibility of direct action of the GABAB receptor antagonist on 
the CB1 receptors. It was also shown that the interaction is 
sterospecific suggesting receptor-mediated action. 
 
2) The specific CB1 antagonist AM251 at a low dose (1 nM) also 
inhibited the efficacy of G-protein signaling of the GABAB 
receptor agonist SKF97541 in rat hippocampal membranes. It is 
speculated that the interaction might occur via an allosteric 
interaction between a subset of GABAB and CB1 receptors in rat 
hippocampal membranes. 
 
3) Cross-talk of the CB1 and GABAB receptor systems was not 
detected in either spinal cord or cerebral cortex membranes. 
These results show that the interaction between CB1 and 
GABAB receptors is tissue specific. 
 
4)  SR141716 (10 µM) significantly decreased the basal 
[35S]GTPγS binding in  membranes of wild-type and CB1 
receptor knock-out mouse cortex, parental Chinese hamster 
ovary (CHO) cells and  CHO cells stably transfected with MOR, 
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MOR-CHO. Accordingly, we conclude that the inverse agonism 
of SR141716 is CB1 receptor-independent. 
 
5) It was demonstrated that SR141716 directly bind to MORs, 
albeit with low affinity.  
 
6) After pertussis toxin (PTX) treatment that uncouples MORs 
from Gi/Go proteins, the inverse agonism of SR141716 was 
abolished, and DAMGO alone displayed weak, naloxone-
insensitive stimulation. Notably, the combination of DAMGO 
and SR141716 (10 µM each) resulted in a 169 ± 22% 
stimulation of the basal activity that was completely inhibited by 
the prototypic opioid antagonist naloxone in MOR-CHO 
membranes, thereby revealing novel, non-PTX mediated G-
protein signaling of MOR. 
 
7) Chronic morphine treatment caused desensitization of the novel 
G-protein signaling induced by co-addition of DAMGO and 
SR141716 to MOR-CHO. 
 
Consequently, these data revealed reciprocal inhibition of 
G-protein signaling induced by CB1 and GABAB receptors in rat 
hippocampus. It is intriguing that the cross-talk between CB1 and 
GABAB receptors might be involved in balance tuning the 
endocannabinoid and GABAergic signaling in hippocampus. In 
addition, CB1 receptor-independent actions of SR141716 occurred on 
G-protein signaling. Its co-application with the µ-opioid agonist 
DAMGO unmasked novel, pertussis toxin-insensitive opioid 
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signaling in MOR-CHO cells. We concluded that SR141716 exerts 
multifaceted effects on G-protein signaling. It is anticipated that it 
may also affect the signaling of other GPCRs. The multifaceted 
actions of the SR141716 should be taken into account when 
applied in high doses in the clinics. 
Receptor and ligand interactions at new levels reveal 
previously not recognized complexity of receptor functioning that 
may provide important data for both basic and pharmaceutical 
research fields. 
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